• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Navidea Biopharmaceuticals Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

    4/14/23 8:26:50 AM ET
    $CXAI
    $FRGT
    $GMVD
    $HTCR
    EDP Services
    Technology
    Professional Services
    Consumer Discretionary
    Get the next $CXAI alert in real time by email

    Gainers

    • CXApp Inc. (NASDAQ:CXAI) jumped 318% to $29.80 in pre-market trading after gaining more than 345% on Thursday.
    • SAI.TECH Global Corporation (NASDAQ:SAI) gained 211% to $4.73 in pre-market trading after gaining around 25% on Thursday.
    • Inpixon (NASDAQ:INPX) surged 106% to $1.49 in pre-market trading after jumping around 128% on Thursday.
    • Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) climbed 98.2% to $2.24 in pre-market trading.
    • SMX (Security Matters) Public Limited Company (NASDAQ:SMX) shares climbed 54.3% to $3.50 in pre-market trading after jumping 37% on Thursday.
    • Marpai, Inc. (NASDAQ:MRAI) gained 41% to $2.30 in pre-market trading after gaining 90% on Thursday.
    • LogicMark, Inc. (NASDAQ:LGMK) gained 24.7% to $0.1970 in pre-market trading after gaining around 8% on Thursday.
    • G Medical Innovations Holdings Ltd (NASDAQ:GMVD) gained 23.7% to $0.6572 in pre-market trading. G Medical Innovations recently announced closing of public offering.
    • Navidea Biopharmaceuticals, Inc. (NASDAQ:NAVB) gained 16.5% to $0.3035 in pre-market trading. Navidea Biopharmaceuticals entered into $750,000 asset purchase agreement with Meilleur Technologies for rights to NAV4694.
    • Freight Technologies, Inc. (NASDAQ:FRGT) climbed 15.7% to $3.02 in pre-market trading after declining 9% on Thursday. Freight Technologies recently regained compliance with Nasdaq listing rule.

    Losers

    • Navidea Biopharmaceuticals (NASDAQ:NCMI) fell 27% to $0.3124 in pre-market trading. The company recently filed a voluntary Chapter 11 petition in the U.S. Bankruptcy Court for the Southern District of Texas. The company announced a series of debt restructuring transactions likely to strengthen its balance sheet meaningfully and position it for long-term growth.
    • Pear Therapeutics, Inc. (NASDAQ:PEAR) shares dropped 24.4% to $0.0896 in pre-market trading. Pear Therapeutics recently filed for Chapter 11 and said it will seek to sell its assets through a sales process.
    • PARTS iD, Inc. (NYSE:ID) fell 21.9% to $0.1926 in pre-market after dropping over 5% on Thursday.
    • SAB Biotherapeutics, Inc. (NASDAQ:SABS) fell 20.5% to $0.6029 in pre-market trading. SAB Therapeutics shares jumped around 98% on Thursday after the company said it has been granted Fast Track designation from the FDA for SAB-176 influenza immunotherapy with high cross-reactivity to multiple strains of influenza.
    • Meta Materials Inc. (NASDAQ:MMAT) fell 20.2% to $0.3050 in pre-market trading after the company reported a proposed public offering.
    • Panbela Therapeutics, Inc. (NASDAQ:PBLA) fell 18.8% to $0.47 in pre-market trading. Panbela Therapeutics recently announced the first patient has been enrolled in the Phase II trial of CPP-1X-T.
    • Kalera Public Limited Company (NASDAQ:KAL) fell 17.3% to $1.34 in pre-market trading after dropping 14% on Thursday. Kalera recently received a notice of delisting form Nasdaq.
    • Wheels Up Experience Inc. (NYSE:UP) fell 17.1% to $0.44 in pre-market trading after gaining around 27% on Thursday.
    • HeartCore Enterprises, Inc. (NASDAQ:HTCR) fell 15.1% to $1.01 in pre-market trading after dropping 15% on Thursday. HeartCore Enterprises recently announced it signed its tenth Go IPO contract.
    • Knightscope, Inc. (NASDAQ:KSCP) shares fell 13.6% to $0.55 in pre-market trading after dropping over 6% on Thursday.

    Now Read This: S&P 500 Settles Higher Ahead Of Bank Earnings, Market Volatility Decreases

    Get the next $CXAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CXAI
    $FRGT
    $GMVD
    $HTCR

    CompanyDatePrice TargetRatingAnalyst
    SAB Biotherapeutics Inc.
    $SABS
    12/19/2025$15.00Buy
    Guggenheim
    National CineMedia Inc.
    $NCMI
    10/31/2025$7.00 → $6.50Outperform
    Barrington Research
    SAB Biotherapeutics Inc.
    $SABS
    9/17/2025$7.00Outperform
    Leerink Partners
    National CineMedia Inc.
    $NCMI
    5/16/2025$6.00Buy → Neutral
    B. Riley Securities
    SAB Biotherapeutics Inc.
    $SABS
    5/14/2025$10.00Buy
    H.C. Wainwright
    National CineMedia Inc.
    $NCMI
    3/14/2025$7.50Neutral → Outperform
    Wedbush
    Knightscope Inc.
    $KSCP
    1/30/2025$16.00Buy
    H.C. Wainwright
    SAB Biotherapeutics Inc.
    $SABS
    10/9/2024$11.00Buy
    Craig Hallum
    More analyst ratings

    $CXAI
    $FRGT
    $GMVD
    $HTCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Freudenthaler Paul D

    3 - Freight Technologies, Inc. (0001687542) (Issuer)

    3/19/26 6:43:56 AM ET
    $FRGT
    Professional Services
    Consumer Discretionary

    SEC Form 3 filed by new insider Gonzalez Leon Jose Andres

    3 - Freight Technologies, Inc. (0001687542) (Issuer)

    3/19/26 6:40:35 AM ET
    $FRGT
    Professional Services
    Consumer Discretionary

    SEC Form 3 filed by new insider Selgas Javier

    3 - Freight Technologies, Inc. (0001687542) (Issuer)

    3/19/26 6:38:04 AM ET
    $FRGT
    Professional Services
    Consumer Discretionary

    $CXAI
    $FRGT
    $GMVD
    $HTCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eitan Yaron bought $100,000 worth of shares (100,000 units at $1.00), increasing direct ownership by 10% to 1,089,073 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:50:17 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Shiv Sagiv bought $50,000 worth of shares (50,000 units at $1.00), increasing direct ownership by 23% to 272,000 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:49:18 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Pons Robert M bought $50,000 worth of shares (50,000 units at $1.00), increasing direct ownership by 16% to 359,200 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:47:30 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $CXAI
    $FRGT
    $GMVD
    $HTCR
    SEC Filings

    View All

    SEC Form 6-K filed by Freight Technologies Inc.

    6-K - Freight Technologies, Inc. (0001687542) (Filer)

    3/19/26 5:28:08 PM ET
    $FRGT
    Professional Services
    Consumer Discretionary

    SEC Form 424B5 filed by SAB Biotherapeutics Inc.

    424B5 - SAB Biotherapeutics, Inc. (0001833214) (Filer)

    3/17/26 4:00:53 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Freight Technologies Inc.

    6-K - Freight Technologies, Inc. (0001687542) (Filer)

    3/16/26 9:00:03 AM ET
    $FRGT
    Professional Services
    Consumer Discretionary

    $CXAI
    $FRGT
    $GMVD
    $HTCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Freight Technologies Releases Pro Forma Financial Statements for JAK Solar Acquisition

    HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Freight Technologies, Inc. (NASDAQ:FRGT, "Fr8Tech" or the "Company")), a logistics management innovation company offering a diverse portfolio of technology-driven solutions, today released the unaudited pro forma financial statements related to its acquisition of JAK Solar Loans 1 Limited ("JAK Solar"), which was completed on December 31, 2025. The unaudited pro forma condensed combined financial information includes a balance sheet as of September 30, 2025 and statements of operations for the nine months ended September 30, 2025 and the year ended December 31, 2024. The pro forma financial statements have been prepared in accordance with Articl

    3/19/26 5:50:45 PM ET
    $FRGT
    Professional Services
    Consumer Discretionary

    SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

    MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the closing of an underwritten public offering of 19,324,677 shares of its common stock at a public offering price of $3.85 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 2,753,246 shares of common stock at a public offering price of $3.8499 per pre-funded warrant, which represents the per share public offering price less the $0.0001 per share exercise price for each pre-funded war

    3/19/26 4:01:00 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

    MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the pricing of an underwritten public offering of 19,324,677 shares of its common stock at a public offering price of $3.85 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 2,753,246 shares of common stock at a public offering price of $3.8499 per pre-funded warrant, which represents the per share public offering price less the $0.0001 per share exercise price for each pre-funded war

    3/17/26 10:46:23 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CXAI
    $FRGT
    $GMVD
    $HTCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on SAB BIO with a new price target

    Guggenheim initiated coverage of SAB BIO with a rating of Buy and set a new price target of $15.00

    12/19/25 8:51:08 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barrington Research reiterated coverage on National Cinemedia with a new price target

    Barrington Research reiterated coverage of National Cinemedia with a rating of Outperform and set a new price target of $6.50 from $7.00 previously

    10/31/25 7:55:49 AM ET
    $NCMI
    Advertising
    Consumer Discretionary

    Leerink Partners initiated coverage on SAB BIO with a new price target

    Leerink Partners initiated coverage of SAB BIO with a rating of Outperform and set a new price target of $7.00

    9/17/25 8:03:24 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CXAI
    $FRGT
    $GMVD
    $HTCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    12/9/24 5:14:07 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13D/A filed by LogicMark Inc.

    SC 13D/A - LogicMark, Inc. (0001566826) (Subject)

    12/3/24 3:35:39 PM ET
    $LGMK
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13D/A filed by National CineMedia Inc.

    SC 13D/A - National CineMedia, Inc. (0001377630) (Subject)

    11/20/24 9:34:56 PM ET
    $NCMI
    Advertising
    Consumer Discretionary

    $CXAI
    $FRGT
    $GMVD
    $HTCR
    Financials

    Live finance-specific insights

    View All

    National CineMedia, Inc. Reports Results for Fiscal Fourth Quarter and Full Year 2025

    Fourth quarter operating income increases year-over-year and fourth quarter adjusted OIBDA exceeds guidance Fourth quarter revenue growth of 8% outpaced attendance as NCM attracted greater advertiser demand National CineMedia, Inc. (NASDAQ:NCMI) (the "Company" or "NCM"), the managing member of National CineMedia, LLC (NCM LLC), the operator of the largest cinema advertising platform in the U.S., announced today its consolidated results for the fiscal fourth quarter and year ended January 1, 2026. "NCM expanded fourth quarter revenue by 8% year-over-year, demonstrating the returns from our continued investment in our platform over the course of the year," said Tom Lesinski, Chief Execu

    2/26/26 4:05:00 PM ET
    $AMC
    $CNK
    $NCMI
    Movies/Entertainment
    Consumer Discretionary
    Advertising

    National CineMedia, Inc. to Release Fourth Quarter and Full Year 2025 Results on February 26, 2026

    National CineMedia, Inc. (NASDAQ:NCMI), the managing member of National CineMedia, LLC ("NCM LLC"), the operator of the largest cinema advertising platform in the U.S., plans to issue its fourth quarter and full year 2025 earnings results after the market closes on Thursday, February 26, 2026. A conference call and audio webcast to discuss the results will take place at 5:00 p.m. Eastern Time. The conference call can be accessed by dialing 1-844-826-3033 or for international participants 1-412-317-5185. Participants should register at least 15 minutes prior to the commencement of the call to register, download, and install necessary audio software. Additionally, a live audio webcast will

    2/19/26 4:05:00 PM ET
    $AMC
    $CNK
    $NCMI
    Movies/Entertainment
    Consumer Discretionary
    Advertising

    Wheels Up Announces Date of Fourth Quarter 2025 Earnings Release

    ATLANTA, Feb. 5, 2026 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that it will release its fourth quarter 2025 financial results on Thursday, February 19, 2026. Earnings materials will be available on the Wheels Up investor relations website at investors.wheelsup.com. About Wheels Up Wheels Up is a leading global provider of on-demand private aviation with a large, diverse fleet and a network of safety-vetted charter operators, all committed to safety and service. Customers access charter and membership programs and premium commercial travel benefits th

    2/5/26 8:00:00 AM ET
    $UP
    Transportation Services
    Consumer Discretionary

    $CXAI
    $FRGT
    $GMVD
    $HTCR
    Leadership Updates

    Live Leadership Updates

    View All

    MARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTH

    TAMPA, Fla., Jan. 27, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced the hiring of Mimi Davis as President of MarpaiRx. Davis, a distinguished leader in the pharmacy services sector, will oversee the strategic expansion and operational scaling of Marpai's pharmacy benefit offerings. Davis joins Marpai from Knipper Health, where she served as Executive Vice President of Operations. Her deep industry roots include a significant tenure at Eagle Pharmacy—a former HillCour portfolio company—which was acquired by Knipper in 2020. With

    1/27/26 8:23:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

    David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D. to its Board of Directors as Chair of the Board and the appointment of Rita Jain, M.D., as an independent director, both effective immediately. "We are excited to welcome Dr. David Zaccardelli and Dr. Rita Jain to our Board of Directors. I, along with the rest of our Board, am confi

    1/7/26 8:00:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    La Rosa Holdings Corp. Announces Appointment of Nicholas Adler as Chairman of the Board and Chairman of the Compensation Committee

    Celebration, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- La Rosa Holdings Corp. (NASDAQ: LRHC) ("La Rosa" or the "Company"), a real estate and PropTech company, today announced that the Company's Board of Directors (the "Board") has appointed Mr. Nicholas Adler as a member of the Board, effective December 29, 2025. Upon his appointment, Mr. Adler was also named Chairman of the Board, Chairman of the Compensation Committee, and a member of both the Audit Committee and the Nominating and Corporate Governance Committee. Additionally, on December 29, 2025, Mr. Siamack Alavi notified the Board of his resignation as a director of the Company, effective immediately. Mr. Alavi also stepped down from hi

    12/30/25 8:30:00 AM ET
    $FRGT
    $LRHC
    Professional Services
    Consumer Discretionary
    Real Estate
    Finance